What is the difference between gaba and glutamate

Glutamate is the metabolic precursor of GABA, which can be recycled through the tricarboxylic acid cycle to synthesize glutamate. GABA synthesis is unique among neurotransmitters, having two separate isoforms of the rate-controlling enzyme, glutamic acid decarboxylase. The need for two separate genes on two chromosomes to control GABA synthesis is unexplained. GABA can also be taken up by presynaptic neurons after its release into the synapsis. A total of five subunits are arranged around the central ion pore.

The subsequent influx of anions hyperpolarizes the membrane phasic inhibition. Metabotropic G-protein coupled GABA B receptors are mostly located extrasynaptically and can be found both pre- and the postsynaptical. Activation of postsynaptical GABA B receptors reduces depolarization of the plasma membrane and thereby modulates excitatory signals. The relation between anti-GluR antibodies Abs with limbic encephalitis has been investigated during the last two decades [ 62 , 63 ].

The affected patients develop complex neuropsychiatric symptoms, such as memory deficits, cognition impairment, psychosis, seizures, abnormal movements, or coma. These disorders affect mainly young women, though cases of men and children have been reported [ 62 ]. Some of these patients present with malignant tumors and the syndrome can be qualified as paraneoplastic [ 62 ], characterized by association of anti-NMDA-RAb in ovarian teratoma and anti-AMPA-RAb in lung small cell carcinoma.

Paraneoplastic limbic encephalitis can be fatal, but is curable if treated at an early stage by surgical removal of the tumor and a combination of immunotherapeutic agents [ 62 ].

Anti-mGluR1Ab was reported in two patients with malignant lymphoma and one patient with prostate adenocarcinoma [ 67 , 68 ]. One of these involves mutations in the GRM1 gene, which encodes mGluR1, known to play an important role in cerebellar differentiation [ 70 ].

Accordingly, the clinical features of this familial form of CAs appear already during childhood. The child shows global developmental delay, intellectual defects, severe CAs, and pyramidal signs.

Brain imaging often shows progressive generalized cerebellar atrophy. Mutations affect a gene region critical for alternative splicing and the formation of the receptor structure. Deficits and mutations in GluR can also affect the level of extracellular glutamate with detrimental outcomes for neurotransmission and neuronal health.

The combination of these two changes ultimately leads to mitochondrial dysfunction and cell death [ 73 ]. Taken together, glutamate-induced excitotoxicity may be a common process for neuronal death throughout the CNS and accelerates the original pathological changes.

Some patients also develop CAs. Clinical studies indicate that surgical removal of the lung tumor and subsequent immunotherapy can be effective in the relief of the above neurological disorders, especially in the early stages of disease. SPS is characterized clinically by progressive rigidity and painful-muscle spasms in the axial and limb muscles.

Electromyography EMG shows simultaneous activities of the agonist and antagonistic muscles. Furthermore, the majority of patients also suffer from type 1 diabetes mellitus T1D [ 76 ]. However, recent studies have shed new light on this issue. Specifically, IgGs obtained from the CSF of patients with anti-GAD65Ab-associated CA depressed GABA release in cerebellar brain slices [ 77 , 78 , 82 , 85 ], and their intracerebellar injection interfered with cerebellar control of the motor cortex and resulted in ataxic gait in rats [ 79 ].

Second, studies in animals have shown internalization of antibodies by cerebellar neurons [ 81 , 86 ], demonstrating that anti-GAD65Ab can access their intracellular target. Together, these results indicate the possibility that anti-GAD65Ab may damage sufficient numbers of GABAergic neurons to result in the appearance of frank neurological symptoms [ 87 ]. The pathological effects of anti-GAD65Ab depend on epitope specificity. This epitope dependence might explain the differences in neurological phenotypes.

An alternative explanation of the phenotypic differences is the involvement of other autoimmune-mediated mechanisms. Under normal conditions, the released GABA spills over to the neighboring excitatory synaptic terminals and inhibits presynaptic glutamate release through GABA receptors. The imbalance between GABA and glutamate is accelerated following the involvement of microglia and astrocytes [ 87 ]. Thus, the neuroinflammation-induced chain reactions accelerate the imbalance, leading to profound excitotoxicity.

In agreement with this notion, the cerebellar neurons are completely lost in patients with advanced stage CAs [ 90 ]. The imbalance between glutamate and GABA can trigger excitotoxicity, one of several neuron death mechanisms. While GABA and glutamate are best characterized for their role as neurotransmitter, they are also involved in extra-neuronal signaling.

As a major building block in proteins synthesis, intracellular glutamate is abundantly present in the body. In contrast, GABA is present only in restricted non-neuronal tissues, including the pancreas [ 91 ].

Pancreatic islets are clusters of endocrine cells located in the exocrine pancreas and regulate blood glucose homeostasis.

An islet typically contains insulin-releasing beta cells, glucagon-secreting alpha cells, somatostatin-containing delta cells, and pancreatic polypeptide-producing PP cells. The metabolic actions of insulin and glucagon are reviewed in great detail elsewhere [ 92 ]. Briefly, insulin is released at elevated blood glucose levels and acts as an anabolic hormone, causing cellular glucose uptake primarily in skeletal muscles, the liver, and fat tissue.

Here glucose is converted to storable energy substrates including glycogen and triglycerides, respectively. Channels in transporters. Curr Opin Neurobiol 6 — Gerstbrein K, Sitte HH.

Currents in neurotransmitter transporters. A family of genes encoding neurotransmitter transporters. Taurine-induced long-lasting potentiation in the rat hippocampus shows a partial dissociation from total hippocampal taurine content and independence from activation of known taurine transporters. J Neurochem 89 — The betaine-GABA transporter BGT1, slc6a12 is predominantly expressed in the liver and at lower levels in the kidneys and at the brain surface. Eur J Pharmacol —7. Eur J Pharmacol — GABA uptake inhibitors.

Design, molecular pharmacology and therapeutic aspects. Curr Pharm Des 6 — Sindelar M, Wanner KT. Library screening by means of mass spectrometry MS binding assays-exemplarily demonstrated for a pseudostatic library addressing gamma-aminobutyric acid GABA transporter 1 GAT1.

ChemMedChem 7 — Biomed Chromatogr 27 — Synthesis and pharmacological properties of new GABA uptake inhibitors. Pharmacol Rep 64 — Focused pseudostatic hydrazone libraries screened by mass spectrometry binding assay: optimizing affinities toward gamma-aminobutyric acid transporter 1.

J Med Chem 56 — Synthesis of N-substituted acyclic beta-amino acids and their investigation as GABA uptake inhibitors. Eur J Med Chem 65C — Synthesis and evaluation of N-substituted nipecotic acid derivatives with an unsymmetrical bis-aromatic residue attached to a vinyl ether spacer as potential GABA uptake inhibitors. Bioorg Med Chem 21 — Zerangue N, Kavanaugh MP. Flux coupling in a neuronal glutamate transporter.

J Neurosci 18 —8. J Physiol —9. Kinetics of a human glutamate transporter. Neuron 14 — Ion fluxes associated with excitatory amino acid transport. Neuron 15 —8. The uncoupled chloride conductance of a bacterial glutamate transporter homolog. Nat Struct Mol Biol 14 — The glutamate transporter EAAT4 in rat cerebellar Purkinje cells: a glutamate-gated chloride channel concentrated near the synapse in parts of the dendritic membrane facing astroglia.

J Neurosci 18 — Activation of a presynaptic glutamate transporter regulates synaptic transmission through electrical signaling. Nat Neurosci 9 — J Physiol — Water transport in the brain: role of cotransporters. Neuroscience — Gate movements in glutamate transporters. ACS Chem Biol 2 —6. Gouaux E. The molecular logic of sodium-coupled neurotransmitter transporters. Brain glutamate transporter proteins form homomultimers. Trimeric subunit stoichiometry of the glutamate transporters from Bacillus caldotenax and Bacillus stearothermophilus.

Biochemistry 42 —8. Structure of a glutamate transporter homologue from Pyrococcus horikoshii. Nature —8. Shouffani A, Kanner BI.

Cholesterol is required for the reconstruction of the sodium- and chloride-coupled, gamma-aminobutyric acid transporter from rat brain. J Biol Chem —8. Arachidonic acid induces a prolonged inhibition of glutamate uptake into glial cells.

Arachidonic acid inhibits a purified and reconstituted glutamate transporter directly from the water phase and not via the phospholipid membrane. J Biol Chem —5. Differential modulation of human glutamate transporter subtypes by arachidonic acid. Peroxynitrite inhibits glutamate transporter subtypes.

Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration? Trends Pharmacol Sci 19 — Arachidonic acid elicits a substrate-gated proton current associated with the glutamate transporter EAAT4. Nat Neurosci 1 — Arachidonic acid activates a proton current in the rat glutamate transporter EAAT4.

J Biol Chem —7. A pharmacological review of competitive inhibitors and substrates of high-affinity, sodium-dependent glutamate transport in the central nervous system. Curr Pharm Des 5 — Interaction of L-cysteine with a human excitatory amino acid transporter.

Shimamoto K. Glutamate transporter blockers for elucidation of the function of excitatory neurotransmission systems. Chem Rec 8 — DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol 53 — Characterization of novel L-threo-beta-benzyloxyaspartate derivatives, potent blockers of the glutamate transporters. Mol Pharmacol 65 — Grewer C, Grabsch E. Discovery of the first selective inhibitor of excitatory amino acid transporter subtype 1.

J Med Chem 52 —5. Specificity controls for immunocytochemistry. Anat Embryol Berl — Specificity controls for immunocytochemistry: the antigen pre-adsorption test can lead to inaccurate assessment of antibody specificity. J Histochem Cytochem 60 — J Neurosci Res 55 — Expression of the glutamate transporters in human temporal lobe epilepsy.

Neuroscience 88 — The rates of postmortem proteolysis of glutamate transporters differ dramatically between cells and between transporter subtypes. J Chem Neuroanat 30 — The concentrations and distributions of three C-terminal variants of the GLT1 EAAT2; slc1a2 glutamate transporter protein in rat brain tissue suggest differential regulation.

Isolation of current components and partial reaction cycles in the glial glutamate transporter EAAT2. J Neurosci 20 — Comparison of coupled and uncoupled currents during glutamate uptake by GLT-1 transporters. J Neurosci 22 — The discovery of slowness: low-capacity transport and slow anion channel gating by the glutamate transporter EAAT5. Biophys J — Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Extracellular glutamate concentration in hippocampal slice.

J Neurosci 27 — Synaptic activation of glutamate transporters in hippocampal astrocytes. Neuron 19 — The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quantification in young adult rat brain.

J Neurosci 18 —7. Transporters buffer synaptically released glutamate on a submillisecond time scale.

J Neurosci 17 — Intracerebral dialysis and the blood-brain barrier. Concentrations of amino acids in extracellular fluid after opening of the blood-brain barrier by intracarotid infusion of protamine sulfate. J Neurochem 62 — Differential effects of nipecotic acid and 4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridinol on extracellular gamma-aminobutyrate levels in rat thalamus.

Epilepsy Res 95 — Immunocytochemical localization of the GABA transporter in rat brain. J Neurosci 10 — Brain Res Mol Brain Res 26 — GAT-1, a high-affinity GABA plasma membrane transporter, is localized to neurons and astroglia in the cerebral cortex. J Neurosci 15 — Neuronal and glial localization of GAT-1, a high-affinity gamma-aminobutyric acid plasma membrane transporter, in human cerebral cortex: with a note on its distribution in monkey cortex.

J Comp Neurol — Immunoreactivity for the GABA transporter-1 and GABA transporter-3 is restricted to astrocytes in the rat thalamus, a light and electron-microscopic immunolocalization. Neuroscience 83 — Astrocytic processes compensate for the apparent lack of GABA transporters in the axon terminals of cerebellar Purkinje cells.

Immunoreactivity for GABA plasma membrane transporter, GAT-1, in the developing rat cerebral cortex: transient presence in the somata of neocortical and hippocampal neurons. Brain Res Dev Brain Res 99 :1— Brain Res Mol Brain Res 37 — Embryonic and postnatal expression of four gamma-aminobutyric acid transporter mRNAs in the mouse brain and leptomeninges.

GABA transporters in the mammalian cerebral cortex: localization, development and pathological implications. Brain Res Brain Res Rev 45 — Biochim Biophys Acta :4—8. Deletion of the gamma-aminobutyric acid transporter 2 GAT2 and SLC6A13 gene in mice leads to changes in liver and brain taurine contents. Brain Res Mol Brain Res 33 :7— Localization of neuronal and glial glutamate transporters. Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations.

Regional deafferentation down-regulates subtypes of glutamate transporter proteins. J Neurochem 65 —3. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38 — Cellular and regional distribution of the glutamate transporter GLAST in the CNS of rats: nonradioactive in situ hybridization and comparative immunocytochemistry.

J Neurosci 17 :1— Comparative analysis of glutamate transporter expression in rat brain using differential double in situ hybridization. Glutamate transporters in glial plasma membranes: highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry.

Neuron 15 — Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT Science — Neurotox Res 13 — J Neurosci 32 — Glial glutamate transporters mediate a functional metabolic crosstalk between neurons and astrocytes in the mouse developing cortex. Neuron 37 — Contribution of glutamate transporter GLT-1 to removal of synaptically released glutamate at climbing fiber-Purkinje cell synapses. Neurosci Lett —9.

Immunocytochemical localization of a high-affinity glutamate-aspartate transporter, GLAST, in the rat and guinea-pig cochlea. Eur J Neurosci 9 —9. Discrete cellular and subcellular localization of glutamine synthetase and the glutamate transporter GLAST in the rat vestibular end organ. Neuroscience 79 — Derouiche A, Rauen T. J Neurosci Res 42 — Derouiche A. Vision Res 36 —8.

Differential expression of three glutamate transporter subtypes in the rat retina. Cell Tissue Res — High-affinity glutamate transporters in the rat retina: a major role of the glial glutamate transporter GLAST-1 in transmitter clearance. Changing patterns of spatial buffering of glutamate in developing rat retinae are mediated by the Muller cell glutamate transporter GLAST.

Glia-neuron interaction by high-affinity glutamate transporters in neurotransmission. Adv Exp Med Biol — Immunohistochemical localization of the neuron-specific glutamate transporter EAAC1 EAAT3 in rat brain and spinal cord revealed by a novel monoclonal antibody. If benzodiazepines are present, the effectiveness of GABA binding to its receptor is increased significantly Figure Inhibition is produced by increasing the amount of Cl - that flows into the neuron Figure Recognize that benzodiazepines themselves do not open the receptor but simply enhance GABA binding.

Barbiturates also produce their sedative effects by increasing the effectiveness of GABA binding to its receptor. The naturally occurring toxin called picrotoxin is a potent inhibitor of the GABA A receptor and works by preventing Cl - flow through the receptor Figure The glycine receptor, like the GABA A receptor also permits the influx of Cl - into neurons and displays a reversal potential near mV. This Cl - -permeable glycine receptor can be blocked by the rat poison strychnine.

The mature glycine receptor is constructed from mixtures of at least two subunits each of which has four membrane spanning domains. Glutamate GPCRs are members of a large family of receptors that couple with G proteins to produce their effects.

These receptors like those for serotonin, norepinephrine, epinephrine, muscarinic ACh, and dopamine, produce the large majority of their effects through alterations in the activity of metabolic enzymes and not by directly opening ion channels in the membranes.

All of these receptors are single polypeptides that span the membrane seven times See Fig. The glutamate GPCR's best known effects are the activation of phospholipase C which generates inositol-trisphosphate IP 3 and diacylglycerol DAG from the precursor lipid phosphatidylinositol bisphosphate See Figure The GABA B receptor, like the glutamate GPCR, produces its effects not by directly opening ion channels, but by coupling to G-proteins and enzymes that influence metabolites within the neuron.

Some of the ion channel effects detected are due to the components of the activated G-protein binding directly to ion channels, influencing their properties See Figure 6.

Two basic mechanisms, diffusion and high affinity uptake , terminate the response to amino acid transmitters. The high affinity uptake mechanism is the most predominant. The proteins involved in transmitter uptake are related and each contains 12 membrane-spanning domains. Transporters use energy derived either from the hydrolysis of ATP or electrochemical ion gradients established across the membrane to pump the transmitters into neurons and glia.

The energy-dependent nature of these receptors means that in times of metabolic stress, such as during an ischemic episode, the pumps fail and toxic levels of these transmitters build up. The neurotransmitter glutamate is highly toxic to neurons when present for extended periods. One of the best understood clinical conditions involving glutamate is neuronal injury following stroke or trauma.

Both events produce massive release of glutamate in the brain that over-stimulates glutamate receptors. The absence of energy prevents the pumps from removing glutamate from the synapse. The key to minimizing damage following stroke is well-controlled reestablishment of blood flow so that ATP production is supported and homeostasis is reestablished.

Clot breaking agents such as tissue plasminogen activator tPA are now used commonly to reestablish blood flow. Because glutamate is the major excitatory transmitter in the human brain, derangements in glutamate metabolism or receptor activation have been implicated in a wide variety of pathologic conditions. These include diseases such as Alzheimer's and Huntington's chorea.

One explanation for the establishment of focal epilepsy is decreased local GABA-mediated inhibition. Many facets of epilepsy can be elicited experimentally by blocking GABA receptors with the toxin picrotoxin previously described.

The decrease in GABA inhibition permits cells to fire synchronously, thus producing massive local excitation and initiation of a seizure.

Clinically, seizures can often be terminated by inducing a barbiturate coma. High dose barbiturates presumably potentiate GABA's inhibitory effects, preventing local hyperexcitation by hyperpolarizing the cell membranes. Mood disorders generalized anxiety disorder can also be controlled by drugs which potentiate GABA's inhibitory activity. Some of the most widely prescribed drugs-benzodiazepines Librium and Valium -produce their pharmacological effects by increasing GABA's ability to hyperpolarize neuronal membranes, thereby quieting the system.

This finding suggests that some initial imbalance in the GABAergic system may underlie aspects of this disorder. Glutamate is recovered into a usable pool for neurons through it's metabolism in glial cells. Results in its metabolism into glutamine by glutamine synthase.

Results in its metabolism into GABA by glutamic acid decarboxylase. Glutamate is removed from the extracellular space by high-affinity up-take transporters in the plasma membranes of neurons and glia. Glutaminase is an enzyme in neurons that metabolizes glutamine into glutamate.